Grifols announced the buyout of Hologic’s share of their existing JV of the NAT (Nucleic Acid Analysis) donor screening business for $1.85bn. The deal, representing an EV/EBITDA of c.11.6x, brings in R&D and manufacturing (including a plant in San Diego, US) of assays and instruments based on the NAT technology (Grifols already has commercialisation rights). The transaction is expected to be completed by Q1 17.
21 Dec 2016
Acquires Hologic’s share of the NAT unit JV
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Acquires Hologic’s share of the NAT unit JV
Grifols, S.A. Class A (GRF:WBO) | 0 0 1.0% | Mkt Cap: 14,874m
- Published:
21 Dec 2016 -
Author:
Jyoti Prakash -
Pages:
2
Grifols announced the buyout of Hologic’s share of their existing JV of the NAT (Nucleic Acid Analysis) donor screening business for $1.85bn. The deal, representing an EV/EBITDA of c.11.6x, brings in R&D and manufacturing (including a plant in San Diego, US) of assays and instruments based on the NAT technology (Grifols already has commercialisation rights). The transaction is expected to be completed by Q1 17.